Roles of Cyclooxygenase 2 in Sevoflurane- and Olprinone-Induced Early Phase of Preconditioning and Postconditioning Against Myocardial Infarction in Rat Hearts
Free accessOtherFirst published online March, 2011
Roles of Cyclooxygenase 2 in Sevoflurane- and Olprinone-Induced Early Phase of Preconditioning and Postconditioning Against Myocardial Infarction in Rat Hearts
Purpose: It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mechanisms of sevoflurane- and olprinone-induced early-phase preconditioning (E-PreC) and postconditioning (PostC) in rat hearts. Methods: Male Sprague-Dawley rats were anesthetized with sodium pentobarbital. After opening the chest, all rats underwent 30-minute occlusion of left anterior descending coronary artery followed by 2-hour reperfusion, and the infarct size was measured after the reperfusion. The rats were randomly assigned to groups with pre- and postischemic exposure to sevoflurane and administration of olprinone with or without a selective COX-2 inhibitor, NS-398. Results: The infarct size in the control group was 42% ± 6% of the area at risk. Infarct size was significantly reduced by pre- and postischemic administration of sevoflurane (16% ± 7% and 17% ± 6%, respectively), as well as by olprinone (14% ± 4% and 15% ± 10%, respectively). NS-398 prevented the protective effects of both pre- and postischemic exposure to sevoflurane (35% ± 8% and 42% ± 10%, respectively), whereas the protective effect of both pre- and postischemic administration of olprinone was not influenced by NS-398 (12% ± 5% and 19% ± 7%, respectively). Conclusions: Cyclooxygenase 2 could be a critical mediator of sevoflurane-induced but not olprinone-induced E-PreC or PostC in rat hearts.
Gislason GH, Jacobsen S., Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25): 2906-2913.
2.
Salinas G., Rangasetty UC, Uretsky BF, Birnbaum Y.The cycloxygenase 2 (COX-2) story: it’s time to explain, not inflame . J Cardiovasc Pharmacol Ther. 2007 ;12(2):98-111.
3.
Bolli R., Shinmura K., Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55(3):506-519.
4.
Tanaka K., Ludwig LM, Krolikowski JG, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology. 2004;100(3):525-531.
5.
Lutz M., Liu H.Inhaled sevoflurane produces better delayed myocardial protection at48 versus 24 hours after exposure. Anesth Analg. 2006 ;102(4):984-990.
6.
Obal D., Dettwiler S., Favoccia C., Scharbatke H., Preckel B., Schlack W.The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo . Anesth Analg. 2005;101(5):1252-1260.
7.
Ludwig LM, Weihrauch D., Kersten JR, Pagel PS, Warltier DCProtein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. Anesthesiology. 2004;100(3):532-539.
8.
Alcindor D., Krolikowski JG, Pagel PS, Warltier DC, Kersten JRCyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology. 2004 ;100(3):547-554.
9.
Penna C., Mancardi D., Tullio F., Pagliaro P.Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion . Basic Res Cardiol. 2008;103(4):368-377.
10.
Satoh H., Endoh M.Effects of a new cardiotonic agent 1, 2-dihydro-6-methyl-2-oxo-5-[imidazo (1, 2-a) pyridine-6-yl]-3- pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP metabolism in canine ventricular muscle. Jpn J Pharmacol. 1990;52(2):215-224.
11.
Sanada S., Kitakaze M., Papst PJ, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors. Circulation. 2001;104(6):705-710.
12.
Matsumoto S. , Cho S., Tosaka S., et al. Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway. Cardiovasc Drugs Ther.2009;23(4):263-270.
13.
Ye Y., Keyes KT, Zhang C., Perez-Polo JR, Lin Y., Birnbaum Y.The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA . Am J Physiol. 2010;298(5): H1454-H1465.
14.
Conzen PF, Vollmar B., Habazettl H., Frink EJ, Peter K., Messmer K.Systemic and regional hemodynamics of isoflurane and sevoflurane in rats. Anesth Analg. 1992;74(1):79-88.
15.
Patel HH, Hsu AK, Gross GJCOX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat . Life Sci. 2004;75(2): 129-140.
16.
Tosaka S., Makita T., Tosaka R., et al. Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth . 2007;21(2):176-180.
17.
Use T., Makita T., Ureshino H., et al. Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine. Cardiovasc Drugs Ther. 2006;20(5): 327-334.
18.
Gres P., Schulz R., Jansen J., Umschlag C., Heusch G.Involvement of endogenous prostaglandins in ischemic preconditioning in pigs . Cardiovasc Res. 2002;55(3):626-632.
19.
Sato H., Bolli R., Rokosh GD, et al. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol. 2007 ;293(4):H2557-H2564.
20.
Hide EJ, Ney P., Piper J., Thiemermann C., Vane JRReduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 1995;116(5):2435-2440.
21.
Shinmura K. , Tamaki K., Sato T., Ishida H., Bolli R.Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor . Am J Physiol Heart Circ Physiol. 2005;288(5):H2093-H2101.
22.
Bouwman RA, Musters RJ, van Beek-Harmsen BJ, de Lange JJ, Boer C.Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection. Anesthesiology. 2004;100(3):506-514.
23.
Abbate A., Santini D., Biondi-Zoccai GGL, et al. Cyclooxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart. 2004;90(4):440-443.
24.
Engelbrecht AM, Ellis B.Apoptosis is mediated by cytosolic phospholipase A2 during simulated ishaemia/reperfusioninduced injury in neonatal cardiac myocytes. Prostaglandins Leukot Essent Fatty Acids . 2007;77(1):37-43.
Straino S., Salloum FN, Baldi A., et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol . 2007;50(5):571-577.
27.
Saeed SA, Ahmed S.New aspects of cyclooxygenase-2 inhibition in myocardial infarction and ischaemia . Res Commun Mol Pathol Pharmacol. 2005;117-118:167-178.
28.
Kodani E., Shinmura K., Xuan YT, et al. Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. Am J Physiol Heart Circ Physiol. 2001; 281(2):H959-H968.
29.
Salloum FN, Hoke NN, Seropian IM, et al. Parecoxib inhibits apoptosis in acute myocardial infarction due to permaneny coronary ligation but not due to ischemia-reperfusion. J Cardiovasc Pharmacol.2009;53(6):495-498.
